Skip to Content

Insulin Glulisine

In the US, Insulin Glulisine (insulin glulisine systemic) is a member of the drug class insulin and is used to treat Diabetes - Type 1, Diabetes - Type 2, Diabetic Ketoacidosis and Nonketotic Hyperosmolar Syndrome.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antidiabetic agent

Insulin analogue, recombinant human

Insulin with rapid action

Chemical Names

[3B-L-lysine,29B-L-glutamic acid]insulin (human) (WHO)

Insulin (human), 3B-L-lysine,29B-L-glutamic acid]- (USAN)

Foreign Names

  • Insulinum glulisinum (Latin)
  • Insulin glulisin (German)
  • Insulin glulisine (French)
  • Insulina glulisina (Spanish)

Generic Names

Brand Names

  • Apidra
    Sanofi, Dominican Republic; Sanofi, United Kingdom; Sanofi, Guatemala; Sanofi, Ireland; Sanofi, Japan; Sanofi, Panama; Sanofi, Sweden; Sanofi Aventis, Chile; Sanofi Aventis, Spain; Sanofi Oy, Finland; Sanofi-Aventis, Argentina; Sanofi-Aventis, Austria; Sanofi-Aventis, Australia; Sanofi-Aventis, Bosnia & Herzegowina; Sanofi-Aventis, Belgium; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Colombia; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Cyprus; Sanofi-Aventis, Germany; Sanofi-Aventis, Denmark; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Egypt; Sanofi-Aventis, France; Sanofi-Aventis, Georgia; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Honduras; Sanofi-Aventis, Hungary; Sanofi-Aventis, Indonesia; Sanofi-Aventis, Iceland; Sanofi-Aventis, Italy; Sanofi-Aventis, Lebanon; Sanofi-Aventis, Lithuania; Sanofi-Aventis, Latvia; Sanofi-Aventis, Macedonia; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Norway; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Oman; Sanofi-Aventis, Peru; Sanofi-Aventis, Philippines; Sanofi-Aventis, Poland; Sanofi-Aventis, Portugal; Sanofi-Aventis, Romania; Sanofi-Aventis, Serbia; Sanofi-Aventis, Singapore; Sanofi-Aventis, Slovakia; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Thailand; Sanofi-Aventis, Tunisia; Sanofi-Aventis, Turkey; Sanofi-Aventis, Taiwan; Sanofi-Aventis, South Africa; Sanofi-Aventis Group, Russian Federation
  • Apidra SoloStar
    Sanofi-Aventis, Austria; Sanofi-Aventis, Ecuador; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Oman; Sanofi-Aventis, Vietnam; Sanofi-Aventis, South Korea
  • Shorant
    Sanofi-Aventis, Mexico


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.